Originally published by our sister publication Clinical Oncology News
The FDA granted a new indication for talazoparib (Talzenna, Pfizer) with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
Efficacy was evaluated in TALAPRO-2, a randomized, double-blind, placebo-controlled, multi-cohort trial enrolling 399 patients with HRR gene-mutated mCRPC. Patients were randomized in a 1:1 fashion to receive enzalutamide 160 mg